Guardat en:
| Autor principal: | |
|---|---|
| Format: | Recurso digital |
| Idioma: | |
| Publicat: |
Zenodo
2025
|
| Matèries: | |
| Accés en línia: | https://doi.org/10.5281/zenodo.14868929 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Taula de continguts:
- <p>Since the discovery of the bactericidal activity of aminoglycosides, streptomycin, kanamycin,</p> <p>amikacin, and capreomycin (a macrocyclic peptide) have been widely used to treat tuberculosis and</p> <p>multidrug-resistant (MDR) tuberculosis. In general practice, resistance to kanamycin is often used</p> <p>as the sole criterion for defining extensively drug-resistant tuberculosis, assuming that all other</p> <p>drugs in this group or related drugs are resistant to certain strains. However, the assumption of</p> <p>cross-resistance between drugs in the same group is not always true for Mycobacterium</p> <p>tuberculosis. This prompted us to conduct a study to determine the concordance resistance pattern</p> <p>between aminoglycosides and the macrocyclic peptide capreomycin.A total of 2383 mycobacterial</p> <p>strains isolated from suspected MDR cases were subjected to susceptibility testing with</p> <p>aminoglycosides (kanamycin and amikacin), the polypeptide capreomycin, and ofloxacin to</p> <p>determine the resistance pattern. Cultures and susceptibility testing were performed using an</p> <p>automated BACTEC MGIT 960 instrument. Positive susceptibility samples were confirmed by</p> <p>PCR.The results showed that, of the total 2383 strains, 844 (35.41%) were susceptible to all four</p> <p>drugs, and 1539 (64.58%) strains showed resistance in the form of multi- or mono-resistance. The</p> <p>results also showed that of the 474 kanamycin-resistant mycobacterial strains, 86.7% and 77.6%</p> <p>were resistant to amikacin and capreomycin, respectively. Conversely, of the 425 amikacin-</p> <p>resistant mycobacterial strains, 3.3% were susceptible to kanamycin. Our findings suggest that</p> <p>performing susceptibility testing for individual drugs within a class may not provide an accurate</p> <p>strain status and may not be sufficient to make clinical decisions. It is necessary to conduct</p> <p>susceptibility testing of all MDR-TB strains with all aminoglycoside and macrocyclic peptide drugs</p> <p>before subjecting patients to comprehensive drug therapy</p>